Tenaya Therapeutics publishes RIDGE-1 data on TN-401 gene therapy

Kiswahili

Tenaya Therapeutics, Inc. released a slide deck on May 17, 2026, covering results from its RIDGE-1 Phase Ib/II trial of TN-401 gene therapy. The presentation focuses on treatment for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.

The slide deck was issued by the company in connection with the clinical data review. It provides details on the ongoing study of the gene therapy candidate under the ticker TNYA on NASDAQ. No additional outcomes or participant numbers were specified in the release materials.

Makala yanayohusiana

Scientists in a lab celebrating conditional approval of iPS cell products for treating Parkinson's and heart disease.
Picha iliyoundwa na AI

Health ministry panel conditionally approves iPS cell products

Imeripotiwa na AI Picha iliyoundwa na AI

A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.

ProQR Therapeutics presents at TIDES USA 2026

Imeripotiwa na AI

ProQR Therapeutics N.V. published its slide deck for a presentation at the TIDES USA 2026 conference. The materials were released on May 15, 2026, in connection with the company's Q1 earnings summary from May 12.

Afya

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

Biashara

Intellia reports strong phase iii results for hae treatment

Asia

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

ARS Pharmaceuticals reports strong start to 2026 in earnings call

ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.

CK Life unit Sequencio eyes China fast track for cancer vaccines

Imeripotiwa na AI

Sequencio, a new Hong Kong unit of CK Life Sciences, is advancing about 20 cancer vaccine projects via China's faster pathway to human trials. CK Life Sciences vice-president and chief scientific officer Dr Melvin Toh Kean-meng said the firm plans investigator-initiated trials next year.

Gene therapy restores hearing in patients born deaf

A single injection of gene therapy has significantly improved hearing in all ten patients born with a genetic form of deafness, according to a new study. Researchers delivered a working copy of the OTOF gene into the inner ear, with most patients regaining hearing within one month. The treatment, tested in China, proved safe and effective across ages from one to 24.

USC-led trial tests dopamine-producing stem cell implants for Parkinson’s

Imeripotiwa na AI Imethibitishwa ukweli

Doctors at Keck Medicine of USC are implanting lab-grown, dopamine-producing cells into the brains of people with Parkinson’s disease in an early-stage clinical trial that will enroll up to 12 participants across three U.S. sites.

Jumamosi, 16. Mwezi wa tano 2026, 00:33:35

Caribou Biosciences presents car-t updates at healthcare conference

Alhamisi, 7. Mwezi wa tano 2026, 23:02:53

Cytek Biosciences holds first quarter 2026 earnings call

Alhamisi, 30. Mwezi wa nne 2026, 05:54:02

Syntara reports positive FDA feedback on amsulostat trial

Jumatatu, 16. Mwezi wa tatu 2026, 16:23:31

Engineered antibody shrinks tumors body-wide in early cancer trial

Jumanne, 10. Mwezi wa tatu 2026, 18:13:08

Roche shares decline after giredestrant trial fails endpoint

Ijumaa, 6. Mwezi wa tatu 2026, 01:38:54

Evaxion reports improved 2025 financials and transformational clinical progress

Alhamisi, 5. Mwezi wa tatu 2026, 14:37:30

Japan's ministry approves world's first iPS cell treatments for heart failure and Parkinson's

Jumatano, 25. Mwezi wa pili 2026, 06:06:16

Sarepta Therapeutics holds Q4 2025 earnings call

Jumanne, 24. Mwezi wa pili 2026, 21:52:57

AbCellera Biologics publishes Q4 2025 earnings call presentation

Alhamisi, 19. Mwezi wa pili 2026, 19:58:32

Japan panel approves two iPS-derived drugs in world first

 

 

 

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa